Ampion appears to be a one of the more effective anti-inflammatory drugs developed to date and it also appears to be unlike every anti-inflammatory in existence in that it has not shown any adverse side effects. Ampion is a biologic and because it is a naturally occurring substance in the body and because it has a proven safety record for over 40 years as Human Serum Albumen, Ampion is not expected to have any safety concerns. Prior trials have shown compelling efficacy for osteoarthritis knee replacement candidates and there is even an Australian Channel 9 News video testimonial about Ampion's almost miracle like drug performance with no adverse side effects. Ampion is currently in phase III trials and the results are expected to be known before the end of this year. If approved, Ampion has the potential to become a dominant drug in the $65 billion anti-inflammatory market.
Zertane is repurposed Tramadol, used now for the sexual dysfunction of Premature #$%$ that is experienced by an estimated 25% of the male population. The safety of Zertane (Tramadol) has already been proven and approved by the FDA. The FDA has provided guidance for the upcoming Phase III Trial of Zertane that is expected to commence soon. Mike Macaluso, the CEO of Ampio, recently announced at a UBS presentation that the company expects to be making a major announcement "very soon" that a licensing deal to a big pharma partner has been struck. If this happens, company valuations and shares will most likely explode exceeding all time highs.
The company holds several patents on Zertane ED that is regular Zertane combined with PE5 inhibitors such as Viagra. Since Viagra comes off patent soon, it would seem to be of great interest to Pfizer to explore the licensing of Zertane ED to keep their patent holdings alive. Zertane ED has the potential to be the biggest selling sexual dysfunction drug in history.